DNMT3A and acute myeloid leukemia: AML patients were divided into two groups based on their DNMT3A mutation status; the median OS time was 22 months for DNMT3A-mutated patients and 32 months for DNMT3A-wild-type patients, with no statistically significant difference (p>0.05, Figure 2A); similarly, the median RFS of the DNMT3A-mutated group was not significantly different from that of the DNMT3A-wild-type group (10 months vs. 22 months, p>0.05, Figure 2B).